Biogen scraps controversial Alzheimer’s drug Aduhelm
Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer’s in nearly two decades. The pharmaceutical giant is returning the rights to the drug to Neurimmune, the private firm that invented it, and incurring a $60 million one-time charge to close out the Aduhelm
Read More